DGS therapy for cervical esophageal carcinoma or cervical metastasis of esophageal carcinoma PI/II study

DGS therapy for cervical esophageal carcinoma or cervical metastasis of esophageal carcinoma PI/II study - DGS therapy for esophageal cancer PI/II study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014626

Enrollment

Registered

2014-07-23

Start date

2009-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

DGS DCF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: cervical esophageal carcinoma or cervical metastasis of esophageal carcinoma

Exclusion criteria

Exclusion criteria: Regardless of the adjuvant therapy, (tegafur, gimeracil, Oterashiru component of cases TS-capsule with a history of severe hypersensitivity to the 80-containing formulations polysorbate cases and docetaxel there is a treatment history TS-capsule, docetaxel, nedaplatin patients with a history of severe hypersensitivity to the formulation containing platinum or other cases nedaplatin with a history of severe hypersensitivity to the potassium) Cases of disease-free period with active double cancer of less than 5 years Cases (intestinal paralysis, intestinal obstruction, interstitial pneumonia, lung fibrosis, it is difficult to control diabetes, etc.) have a serious complication Cases with active infection Patients with edema requiring treatment Pleural effusion requiring treatment, patients with ascites Patients with a wide range of bone metastases

Design outcomes

Primary

Measure	Time frame
Study of efficacy and safety and the setting of optimal capacity	—

Countries

Japan

Contacts

Public ContactYoshihiro Tanaka

Gifu University Surgical Oncology

yoshihirotana11@hotmail.com0582306000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026